Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.
C-US-PWS-00066
Shared 1 year ago
7.1K views
Shared 1 year ago
244 views
Shared 1 year ago
92 views
Shared 1 year ago
170 views
Shared 2 years ago
4.7K views
Shared 2 years ago
443 views
Shared 2 years ago
287 views
Shared 2 years ago
3.8K views
Shared 2 years ago
305 views
Shared 2 years ago
851 views
Shared 2 years ago
284 views